Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
3(60%)

Phase Distribution

Ph phase_4
2
40%
Ph phase_2
2
40%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 4Post-market surveillance
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(3)

Detailed Status

Terminated3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
40.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 42 (40.0%)

Trials by Status

terminated360%
completed240%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly

NCT06449040
completedphase_2

Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).

NCT02273661
terminatedphase_2

Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL

NCT00832208
terminatedphase_4

Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics

NCT00421187
terminatedphase_4

ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia

NCT00386997

Clinical Trials (5)

Showing 5 of 5 trials
NCT06449040Phase 1

Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly

Completed
NCT02273661Phase 2

Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).

Completed
NCT00832208Phase 2

Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL

Terminated
NCT00421187Phase 4

Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics

Terminated
NCT00386997Phase 4

ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5